Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(17 sites)

United States

Ziaderm Research LLC, North Miami Beach, Florida

Endeavor Health, Glenview, Illinois

France

Novartis Investigative Site, Grenoble

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Paris

Novartis Investigative Site, Pierre-Bénite

Germany

Novartis Investigative Site, Dresden, Saxony

Novartis Investigative Site, Berlin

Novartis Investigative Site, Mainz

Novartis Investigative Site, Tübingen

Poland

Novartis Investigative Site, Poznan

Novartis Investigative Site, Rzeszów

Novartis Investigative Site, Warsaw

Spain

Novartis Investigative Site, Barcelona, Catalonia

Novartis Investigative Site, Pamplona, Navarre

Novartis Investigative Site, Alicante

Novartis Investigative Site, Madrid